Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project
- First Posted Date
- 2005-06-29
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 830
- Registration Number
- NCT00116272
- Locations
- 🇺🇸
Research Site, San Diego, California, United States
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
Phase 3
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2005-06-27
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1053
- Registration Number
- NCT00115765
Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)
Phase 2
Completed
- Conditions
- Breast CancerFeverNeutropenia
- First Posted Date
- 2005-06-23
- Last Posted Date
- 2008-08-01
- Lead Sponsor
- Amgen
- Registration Number
- NCT00115414
Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease
Phase 1
Completed
- Conditions
- Idiopathic Parkinson's Disease
- First Posted Date
- 2005-06-23
- Last Posted Date
- 2008-01-11
- Lead Sponsor
- Amgen
- Registration Number
- NCT00115427
Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-06-22
- Last Posted Date
- 2013-08-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 77
- Registration Number
- NCT00115193
Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy
Phase 4
Completed
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2005-06-22
- Last Posted Date
- 2009-04-06
- Lead Sponsor
- Amgen
- Registration Number
- NCT00115206
Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-06-22
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 200
- Registration Number
- NCT00115219
Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors
- First Posted Date
- 2005-06-22
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 309
- Registration Number
- NCT00115128
A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study
- First Posted Date
- 2005-06-22
- Last Posted Date
- 2009-05-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 371
- Registration Number
- NCT00115167
Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
- First Posted Date
- 2005-06-20
- Last Posted Date
- 2008-10-31
- Lead Sponsor
- Amgen
- Target Recruit Count
- 84
- Registration Number
- NCT00114764
© Copyright 2025. All Rights Reserved by MedPath